Is there an increaed risk of cancer when using spironolactone in patients with hormone positive breast cancer?

Community
Company
News
Contact Us
Sign in

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Non-metastatic

Historical data suggested against use of spironolactone in breast cancer, however contemporary data maybe suggests that there is not an increase in recurrence risk?

Related Questions

In a patient with local recurrence of breast cancer after mastectomy, how would you sequence adjuvant treatment after wide local resection?

As a clinician, what are the management differences between lobular and ductal carcinoma of the breast?

How do you approach the discussion with a patient who is seeking proton therapy for early stage breast cancer?

Given possible lack of benefit findings in subset analysis of Monarch 3, would you still use Abemaciclib in a postmenopausal woman with high-risk ER+ breast cancer?

What adjuvant systemic therapy would you give a patient with ER+/HER2- breast cancer s/p mastectomy, chemo (TC), 5 years of endocrine therapy who presents with nodal recurrence s/p ALND showing 4 involved nodes?

What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?

How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?

How do you respond to a patient who asks "Why do I still need breast radiation after chemotherapy if chemotherapy treats the whole body?"

Would you provide anthracycline-based therapy for early stage node negative triple-negative breast cancer in patient with echocardiogram showing grade 1 diastolic dysfunction?

Would you give KEYNOTE 522 in combination with trastuzumab/pertuzumab neoadjuvantly for multifocal disease?